Post Biocon, Pfizer Pushes Forward On Biosimilar MABs
Executive Summary
Biosimilars pioneers face a steep learning curve and multiple surprises, as shown by Pfizer’s recent and expensive backtrack on its deal with India’s Biocon. But Pfizer says the setback has reaffirmed its strategy as it pushes ahead on its own with a monoclonal antibody program, led by a biosimilar rituximab.
You may also be interested in...
Merck Partners With Korea’s Samsung Bioepis On Multiple Biosimilar Targets
Samsung Bioepis will be responsible for development, manufacturing and registration, while Merck will be responsible for commercializing any resulting drugs. Merck says the partnership will complement the firm’s internal biologics portfolio.
Merck Partners With Korea’s Samsung Bioepis On Multiple Biosimilar Targets
Samsung Bioepis will be responsible for development, manufacturing and registration, while Merck will be responsible for commercializing any resulting drugs. Merck says the partnership will complement the firm’s internal biologics portfolio.
Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.
In most of the world, Germany's Merck Serono will have exclusive rights and India’s Dr. Reddy's will receive royalties on the oncology biosimilars which will be developed as part of the collaboration; but in the U.S. and select emerging markets, the Indian company retains co-commercialization rights.